Key Details
Price
$143.65Annual ROE
-27.16%Beta
1.19Events Calendar
Next earnings date:
Feb 21, 2025Recent quarterly earnings:
Nov 04, 2024Recent annual earnings:
Feb 21, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
The headline numbers for Glaukos (GKOS) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Call Start: 16:30 January 1, 0000 5:31 PM ET Glaukos Corporation. (NYSE:GKOS ) Q3 2024 Earnings Conference Call November 04, 2024, 04:30 PM ET Company Participants Chris Lewis - VP, IR and Corporate Affairs Tom Burns - Chairman and CEO Joe Gilliam - President and COO Alex Thurman - CFO Conference Call Participants Tom Stephan - Stifel Lawrence Biegelsen - Wells Fargo Ryan Zimmerman - BTIG Matthew O'Brien - Piper Sandler Allen Gong - JPMorgan David Saxon - Needham Michael Sarcone - Jefferies Joanne Wuensch - Citigroup Steve Lichtman - Oppenheimer Anthony Petrone - Mizuho Operator Welcome to Glaukos Corporation's Third Quarter 2024 Financial Results Conference Call.
Glaukos (GKOS) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.50 per share a year ago.
Glaukos (GKOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Glaukos announces positive second Phase 3 confirmatory pivotal trial for Epioxa.
GKOS stock is being driven by strong product demand, international expansion and pipeline progress, which position it for long-term growth despite supply risks.
GKOS continues to benefit from a robust product portfolio and a strong pipeline. However, stiff competition remains a woe.
GKOS continues to benefit from a robust demand for its products as well as expansion in new markets. A strong development pipeline raises optimism.
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
While the top- and bottom-line numbers for Glaukos (GKOS) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
FAQ
- What is the primary business of Glaukos?
- What is the ticker symbol for Glaukos?
- Does Glaukos pay dividends?
- What sector is Glaukos in?
- What industry is Glaukos in?
- What country is Glaukos based in?
- When did Glaukos go public?
- Is Glaukos in the S&P 500?
- Is Glaukos in the NASDAQ 100?
- Is Glaukos in the Dow Jones?
- When was Glaukos's last earnings report?
- When does Glaukos report earnings?
- Should I buy Glaukos stock now?